Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry

  • Karl B. ScheidweilerEmail author
  • Allan J. Barnes
Part of the Methods in Molecular Biology book series (MIMB, volume 1872)


Medical and recreational cannabis legalization has highlighted the importance of being able to identify recent cannabis use and impairment. Monitoring minor plant cannabinoids has been proposed to assist in identifying recent cannabis use. Additionally, cannabidiol (CBD) has been proposed for epilepsy, pain, inflammatory disorder, anxiety, and addiction treatment; therefore, monitoring CBD is of increasing clinical importance. However, few methods exist capable of monitoring extensive panels of traditional cannabinoid analytes and minor cannabinoids (including CBD). This chapter details a liquid chromatography tandem mass spectrometry method capable of measuring Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC, cannabinol, cannabigerol, tetrahydrocannabivarin (THCV), and its metabolite, 11-nor-9-carboxy-THCV, in urine.

Key words

Cannabinoids Cannabidiol Urine Liquid chromatography Mass spectrometry Pipette tip extraction 



This research was funded by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health. Recombinant EBG™ β-glucuronidase from E. coli was provided via a Materials Transfer Agreement between the National Institutes of Health and KURA Biotec. The authors thank Yves-Vincent Duperron (KURA Biotec) for his technical assistance.


  1. 1.
    Hall W, Kozlowski LT (2017) The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications. Addiction. CrossRefGoogle Scholar
  2. 2.
    Smith A (2017) 10 things to know about legal pot. Accessed 1 Aug 2017
  3. 3.
    Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA (2013) Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem 59(3):519–526. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aizpurua-Olaizola O, Zarandona I, Ortiz L, Navarro P, Etxebarria N, Usobiaga A (2017) Simultaneous quantification of major cannabinoids and metabolites in human urine and plasma by HPLC-MS/MS and enzyme-alkaline hydrolysis. Drug Test Anal 9(4):626–633. CrossRefPubMedGoogle Scholar
  5. 5.
    Bergamaschi MM, Barnes A, Queiroz RH, Hurd YL, Huestis MA (2013) Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem 405(14):4679–4689. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    ElSohly MA, deWit H, Wachtel SR, Feng S, Murphy TP (2001) Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25(7):565–571CrossRefGoogle Scholar
  7. 7.
    Hidvegi E, Somogyi GP (2010) Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption. Pharmazie 65(6):408–411PubMedGoogle Scholar
  8. 8.
    Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA (1995) Cannabinoids in humans. I. Analysis of delta 9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Toxicol 19(5):285–291CrossRefGoogle Scholar
  9. 9.
    Campbell CT, Phillips MS, Manasco K (2017) Cannabinoids in pediatrics. J Pediatr Pharmacol Ther 22(3):176–185. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825–836. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B (2017) The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology doi: CrossRefGoogle Scholar
  12. 12.
    Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA (2007) Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 31(8):477–485CrossRefGoogle Scholar
  13. 13.
    Andersson M, Scheidweiler KB, Sempio C, Barnes AJ, Huestis MA (2016) Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. Anal Bioanal Chem 408(23):6461–6471. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Skopp G, Potsch L (2002) Stability of 11-nor-delta(9)-carboxy-tetrahydrocannabinol glucuronide in plasma and urine assessed by liquid chromatography-tandem mass spectrometry. Clin Chem 48(2):301–306PubMedGoogle Scholar
  15. 15.
    Sempio C, Scheidweiler KB, Barnes AJ, Huestis MA (2018) Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. Drug Test Anal 10(3):518–529. CrossRefPubMedGoogle Scholar
  16. 16.
    Desrosiers NA, Lee D, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA (2014) In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. Anal Bioanal Chem 406(3):785–792. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Quest DiagnosticsChantillyUSA

Personalised recommendations